Home
Foley & Lardner
Alexandra B. Maulden
Alexandra B. Maulden
Foley & Lardner
New Favorable OIG Advisory Opinion Allows Patient Assistant Programs Funded By Drug Manufacturers
01 May 2024 | United States
Opioid Treatment Programs: SAMHSA Makes Permanent Regulatory Flexibilities
19 Feb 2024 | United States
Behavioral Health: CMS Innovation Model Outlines Changes For The Delivery Of Integrated Behavioral And Physical Health Care
12 Feb 2024 | United States
CMS Expands Access To Behavioral Health Services; Physician Fee Schedule Expands Billing Providers And Flexibilities
15 Nov 2023 | United States
FDA: New Draft Guidance On Communication Of Unapproved Uses Of Approved Or Cleared Medical Products
03 Nov 2023 | United States
FDA's New Enforcement Policy: A Win For Remote Patient Monitoring And Remote Therapeutic Monitoring Manufacturers
01 Nov 2023 | United States
FDA Issues New Warning Regarding Compounded Ketamine
27 Oct 2023 | United States
Clinical Trials: Consent Process Clarified In New FDA Final Guidance
11 Sep 2023 | United States
Gender Affirming Care In Florida: Current Rules Of The Road
24 Aug 2023 | United States
FDA And SAMHSA Issue Joint Statement In Support Of Reducing Barriers To Evidence Based Treatments
23 May 2023 | United States
Gender Affirming Care Restricted Under Missouri Bill
23 May 2023 | United States
Florida's Bill Targeting Gender Affirming Care Impacts Minors And Adults
19 May 2023 | United States
FDA Publishes Framework For Digital Health Technologies In Clinical Trials
16 Apr 2023 | United States
Compliance Officers Lookout! DOJ And OIG Tag Team Corporate Integrity Agreements
14 Nov 2022 | United States
2023 Medicare Physician Fee Schedule Advances Access To Whole Person Treatment For Substance Use Disorders And Behavioral Health
13 Nov 2022 | United States
Contact Details
Boston
Email Website
Boston
United States

  © Mondaq® Ltd 1994 - 2024. All Rights Reserved.